Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 12/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556771 | 0.94 | PDE3B (0.64) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL8551918 | 0.94 | PDE3B (0.64) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL8557091 | 0.94 | PDE3B (0.63) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9672631 | 0.91 | PDE3B (0.59) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9672622 | 0.90 | KCNH2 (0.62) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9672618 | 0.90 | KCNH2 (0.62) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9638770 | 0.88 | KCNH2 (0.60) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9638620 | 0.88 | KCNH2 (0.75) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9638626 | 0.88 | KCNH2 (0.75) | PDE3BPDE3AKCNH2PDE4APDE4B | |
| SCHEMBL9638766 | 0.88 | KCNH2 (0.60) | PDE3BPDE3AKCNH2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2004037262-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| EP-2066174-B1 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170065688-A1 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20140147441-A1 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-29 | — | — | US | disclosed |
| US-8623830-B2 | Compositions containing α-1-antitrypsin and methods for use | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100111940-A1 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2066174-A2 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE | Beth Israel Deaconess Medical Center, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-5891904-A | Use of inhibitors of phosphodiesterase IV | Forssmann, Wolf-Georg (DE) | 1999-04-06 | — | — | US | disclosed |
| EP-0660711-B1 | NOVEL USE OF INHIBITORS OF PHOSPHODIESTERSASE IV | FORSSMANN WOLF GEORG PROF DR (DE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0721950-B1 | Cardioactive 3-alkoxycarbonyl-thiadiazinones | MERCK PATENT GMBH (DE) | 1998-05-06 | — | — | EP | disclosed |
| EP-0758233-A1 | PDE IV INHIBITORS FOR TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-02-19 | — | — | EP | disclosed |
| EP-0721950-A2 | Cardioactive 3-alkoxycarbonyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995028926-A1 | PDE IV INHIBITORS FOR TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-02 | — | — | WO | disclosed |
| WO-1994006423-A1 | NOVEL USE OF INHIBITORS OF PHOSPHODIESTERSASE IV | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | PDE3B 2/4885PDE3A 1/4885KCNH2 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.